The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.
about
Targeting the latent reservoir to achieve functional HIV cureInteraction between Tat and Drugs of Abuse during HIV-1 Infection and Central Nervous System DiseaseHIV-1 functional cure: will the dream come true?Might dolutegravir be part of a functional cure for HIV?Retroviral integration: Site matters: Mechanisms and consequences of retroviral integration site selectionBarriers to HIV Cure.Advancements in Developing Strategies for Sterilizing and Functional HIV Cures.An Ounce of Tat Prevention Is Worth a Pound of Functional Cure.The mTOR Complex Controls HIV Latency.Shutdown of HIV-1 Transcription in T Cells by Nullbasic, a Mutant Tat ProteinChimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving SuppresSpecific Inhibition of HIV Infection by the Action of Spironolactone in T Cells.International AIDS Society global scientific strategy: towards an HIV cure 2016.Residual inflammation and viral reservoirs: alliance against an HIV cure.Role of Host Factors on the Regulation of Tat-Mediated HIV-1 Transcription.Cell-Permeable Peptides Containing Cycloalanine Residues.Synthesis of the Cortistatin Pentacyclic Core by Alkoxide-Directed Metallacycle-Mediated Annulative Cross-Coupling.Didehydro-Cortistatin A: a new player in HIV-therapy?Protein Phosphatase-1 -targeted Small Molecules, Iron Chelators and Curcumin Analogs as HIV-1 Antivirals.HIV-1 Eradication: Early Trials (and Tribulations).Therapeutics Targeting Protein Acetylation Perturb Latency of Human Viruses.Type I interferon responses are impaired in latently HIV infected cells.Recent advances in the identification of Tat-mediated transactivation inhibitors: progressing toward a functional cure of HIV.Improving combination antiretroviral therapy by targeting HIV-1 gene transcription.Novel immunological strategies for HIV-1 eradicationCurrent views on HIV-1 latency, persistence, and cure.HIV-1 Tat and Viral Latency: What We Can Learn from Naturally Occurring Sequence Variations.Interplay between Autophagy, Exosomes and HIV-1 Associated Neurological Disorders: New Insights for Diagnosis and Therapeutic Applications.Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription.Targeting of CDK9 with indirubin 3'-monoxime safely and durably reduces HIV viremia in chronically infected humanized mice.Fate-Regulating Circuits in Viruses: From Discovery to New Therapy Targets.A Novel Bromodomain Inhibitor Reverses HIV-1 Latency through Specific Binding with BRD4 to Promote Tat and P-TEFb Association.Shock and kill with caution.Will LEDGIN molecules be able to play a role in a cure for HIV infection?FISHing Out the Hidden Enemy: Advances in Detecting and Measuring Latent HIV-Infected Cells.Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a "Block-and-Lock" Strategy for HIV-1 Treatment.HIV-1 Tat protein induces DNA damage in human peripheral blood B-lymphocytes via mitochondrial ROS production.Curaxin CBL0100 Blocks HIV-1 Replication and Reactivation through Inhibition of Viral Transcriptional Elongation.RNA Interference Therapies for an HIV-1 Functional Cure.
P2860
Q26745923-B7D04D25-8880-422A-AB16-D7C7AE029FF3Q26770397-5B1C2807-C71C-462E-AD54-2C255AEED148Q26865803-3A274C61-FD16-4C36-82EC-208C3A266171Q28071420-3F19F989-AC2B-448A-818E-0EB038FCC753Q28088514-FD0249DF-C9BD-4556-980D-002178EC04E5Q30245414-1E749FB8-E463-4ED2-B8AE-8E61E68B7C53Q33654409-69F58408-98F5-4647-9431-42498499B83CQ35973026-FC879C07-5901-4FBE-92B0-4EF68D14BB2CQ36225471-5E05A9EC-C212-4669-9C64-A1CB640AE687Q37120233-41F5BE40-D7D0-4C3D-B6A8-75C36D1383DAQ37347313-0A90143E-829D-454D-949C-2C99A74CEF97Q37415393-EDBA0290-9E77-4856-8DDE-C69111F8F9B5Q37661770-E45CC24B-FAF0-496C-8C93-F23FA3FDF396Q38269458-ACC0E644-64E3-4F77-9CE4-7AE883A8245EQ38430337-56E57AD4-FB1A-4B6A-9D4F-1EAB32D7465FQ38436470-B8DE1268-460D-4DAA-8318-DC9FD52153F1Q38437941-02E4331F-F706-4F1E-BDA7-80455EAB3AE1Q38440932-5CF060BA-D950-4498-9A2A-AA0E22B6CA96Q38662748-D16D8D64-4ED2-4C62-A630-A2763949668FQ38675631-053A6512-DF81-4040-98CA-953AFB3C708AQ38723116-DE467F38-A131-4F5E-965D-689EE941B550Q38747126-E84D4377-B5E4-446C-8CEA-452544103AF0Q38757713-74BC3F5F-E5BC-4846-AE8C-2895E79B5433Q38856263-FEFA24F7-3A80-4B65-80AE-C8188C1B2956Q38915896-EC5A2B07-F172-4558-AFCE-95E7F6D83F66Q38973362-B54EEA6C-1BB7-4E3E-A677-93C0A41C9080Q39134277-DFD8C248-32FE-40E3-8A15-5DCCF6FF6362Q39419450-4D3A0330-01C3-4A1C-987D-7336AEBB4578Q40070005-4989BF36-C6C2-4EA4-B07F-CE5ECD3BA555Q40079572-6D16C526-6E73-4BDE-9E24-4AB689E88243Q40086009-C45F32FF-2BA1-4445-8BA9-9CA587979F08Q40150438-57DFF455-DA81-4293-9C0C-E942336DDF9AQ40507710-D1A19AB2-2EED-498E-A9E5-2D193E0F635EQ40609511-F9F177CD-9D38-4A7A-B580-E3F264CAAEA8Q41676254-31815835-2907-4469-963B-6321442445AEQ41918728-C2A0052B-033C-4707-B7B4-3EAFEF7FF1CDQ42381408-D2EFC5FB-89AF-49FD-9AA8-A31DF063F2A6Q46245165-39D8B3C2-379B-46AC-9EB1-B9120DDE5385Q47201695-FB68A5ED-75C7-4EDF-B463-74F511871BC6Q47252129-D7E17162-4344-43CD-9F13-43CDFC7DF68D
P2860
The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.
@ast
The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.
@en
type
label
The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.
@ast
The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.
@en
prefLabel
The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.
@ast
The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.
@en
P2093
P2860
P356
P1433
P1476
The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.
@en
P2093
Cari F Kessing
Guillaume Mousseau
Rémi Fromentin
Susana T Valente
P2860
P304
P356
10.1128/MBIO.00465-15
P577
2015-07-07T00:00:00Z